New dupixent® (dupilumab) analyses at two upcoming dermatology congresses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

Tarrytown, n.y., april 23, 2021 /prnewswire/ --  nearly 30 data presentations at aad and espd highlight the impact of dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life in clinical and real-world settings regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that new analyses of dupixent® (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis will be presented at the american academy of dermatology annual meeting (aad vmx 2021) from april 23-25, and at the 20th european society for pediatric dermatology annual meeting (espd 2021) from may 12-14.
REGN Ratings Summary
REGN Quant Ranking